AZN · story · 5 November
AstraZeneca · 14 headlines from 11 outlets, on 5 November 2026.
WSJ reported AstraZeneca made a $10bn offer for Rhythm, whose shares jumped about 28%.
The story's tone is the average of its headlines' own scores. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone.
Traders Union is the largest at 5.5, ahead of Reuters (5.0). Yahoo Finance is the smallest at 3.3.
Source: MarketFrame news analysis
| outlet | Average tone |
|---|---|
| TradingView | 4.2 |
| Traders Union | 5.5 |
| Reuters | 5.0 |
| WSJ | 5.0 |
| MarketScreener | 5.0 |
| investingLive | 5.0 |
| 1470 & 100.3 WMBD | 5.0 |
| BigGo Finance | 4.7 |
| Finimize | 4.5 |
| Yahoo Finance | 3.3 |
| Outlet | Headlines | Average tone |
|---|---|---|
| TradingView | 4 | +4.2 |
| Traders Union | 1 | +5.5 |
| Reuters | 1 | +5.0 |
| WSJ | 1 | +5.0 |
| MarketScreener | 1 | +5.0 |
| investingLive | 1 | +5.0 |
| 1470 & 100.3 WMBD | 1 | +5.0 |
| BigGo Finance | 1 | +4.7 |
| Finimize | 1 | +4.5 |
| Yahoo Finance | 1 | +3.3 |
| Outlet | Headlines | Average tone |
|---|---|---|
| Investing.com Nigeria | 1 | +3.3 |
One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.
| Tone | What the article reported, and why it scored that way |
|---|---|
| +5.5 | Bid framed as strategic move into rare obesity treatments. |
| +5.0 | Reuters sources confirm big approach to obesity drug company. |
| +5.0 | Original report of large offer for Rhythm. |
| +5.0 | Large acquisition approach expanding obesity and rare disease pipeline. |
| +5.0 | Report of sizeable offer for obesity-focused drugmaker. |
| +5.0 | Syndicated report of large offer for obesity drugmaker. |
| +5.0 | Another report of large offer for Rhythm. |
| +5.0 | Another report of large offer for Rhythm. |
| Tone | What the article reported, and why it scored that way |
|---|---|
| +4.7 | Possible large purchase; target's shares rose sharply. |
| +4.5 | Considering sizeable bid for obesity-focused rival. |
| +3.3 | Target stock rally driven by AstraZeneca approach. |
| +3.3 | Target shares jump on reported approach from AstraZeneca. |
| +3.3 | Target jumps on reported approach from AstraZeneca. |
| +3.3 | Target shares jump on reported approach from AstraZeneca. |
A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.